Recurrent Glioblastoma Multiforme (GBM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 In adults, glioblastoma (GBM) stands as the most aggressive primary malignancy affecting the central nervous system (CNS), typically diagnosed at a median age of 65 years. Standard treatment for newly diagnosed GBM involves surgical resection to the fullest extent deemed safe, accompanied by concurrent radiotherapy and temozolomide (TMZ), followed by six-monthly cycles of adjuvant TMZ. However, options become limited when tumors progress beyond initial therapy, posing significant challenges in managing recurrent GBM (rGBM). Recurrence of GBM is virtually inevitable within a median survival period of 32–36 weeks, attributed to several factors, including the absence of a consistent definition and criteria for tumor recurrence, variations in institutional treatment approaches, and the complex, heterogeneous nature of the disease. Recurrence commonly manifests at the original tumor site in more than 90% of cases, while approximately 5% develop multiple lesions post-treatment. Additionally, GBM recurrence may occur through the emergence of new parenchymal lesions exhibiting non-continuous growth patterns, intraventricular spread, or dissemination, albeit less frequently.

·       GBM ranks as the most prevalent malignant brain tumor in adults, with an overall incidence of 3.19 per 100,000 individuals and a prevalence of 9.23 per 100,000 individuals in the United States.

 

Thelansis’s “Recurrent Glioblastoma Multiforme (GBM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Glioblastoma Multiforme (GBM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

 

KOLs insights of Recurrent Glioblastoma Multiforme (GBM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Recurrent Glioblastoma Multiforme (GBM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Recurrent Glioblastoma Multiforme (GBM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Tags: Recurrent Glioblastoma Multiforme (GBM), Recurrent Glioblastoma Multiforme (GBM) market outlook, Recurrent Glioblastoma Multiforme (GBM) competitive landscape, Recurrent Glioblastoma Multiforme (GBM) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)